Synthetic Biology and GenScript

The rapidly expanding science of synthetic biology is a field that GenScript, the leading synthetic biology company in the world and the No. 1 gene synthesis supplier in North America, has helped pioneer since 2002. Since de novo gene synthesis is not dependent on naturally occurring DNA templates, sequences can be generated that encode for novel proteins, metabolic circuits or whole genomes. With the advent of novel DNA parts, there are few limitation towards advancing synthetic biology.

The discovery of the CRISPR/Cas9 gene editing technology has vastly accelerated the field of synthetic biology, enabling the development of novel cell lines and synthesis of important metabolites and proteins. With a license from the only CRISPR patent holder, GenScript strives to facilitate CRISPR research by offering a variety of gRNA constructs, genome-wide libraries, as well as CRISPR-edited mammalian cell lines and microbes. In 2016, GenScript is offering sponsorship opportunities for iGEM teams striving to advance the potential of CRISPR gene editing.